Clinical Trial Update: Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating gefitinib as first-line therapy in Caucasian patients with EGFR mutation-positive advanced non-small cell lung cancer, reporting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Caucasian Patients With EGFR Mutation Positive Advanced NSCLC | Phase 4 | Status: COMPLETED | Results posted: 2013-10-14